Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own0.20% Shs Outstand41.31M Perf Week-13.41%
Market Cap557.69M Forward P/E- EPS next Y-3.43 Insider Trans38.58% Shs Float38.07M Perf Month-11.99%
Income-100.20M PEG- EPS next Q-0.86 Inst Own63.80% Short Float34.56% Perf Quarter-40.08%
Sales12.40M P/S44.97 EPS this Y35.60% Inst Trans-3.11% Short Ratio7.63 Perf Half Y-58.11%
Book/sh6.97 P/B1.94 EPS next Y-8.90% ROA-32.80% Target Price26.92 Perf Year-28.91%
Cash/sh5.71 P/C2.36 EPS next 5Y-0.20% ROE-37.70% 52W Range12.58 - 40.00 Perf YTD-33.73%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-36.30% 52W High-65.64% Beta0.66
Dividend %- Quick Ratio11.90 Sales past 5Y-7.80% Gross Margin- 52W Low9.26% ATR0.90
Employees146 Current Ratio11.90 Sales Q/Q-73.80% Oper. Margin- RSI (14)36.39 Volatility8.54% 5.97%
OptionableYes Debt/Eq0.01 EPS Q/Q42.70% Profit Margin- Rel Volume0.64 Prev Close13.50
ShortableYes LT Debt/Eq0.01 EarningsNov 06 BMO Payout- Avg Volume1.72M Price13.74
Recom2.40 SMA20-9.96% SMA50-19.05% SMA200-43.54% Volume792,210 Change1.81%
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Oct-28-14Downgrade Robert W. Baird Outperform → Neutral $53 → $21
Aug-01-14Initiated Oppenheimer Outperform $45
Jul-29-14Upgrade WBB Securities Speculative Buy → Buy $25
Apr-22-14Reiterated Needham Buy $36 → $52
Apr-22-14Reiterated Deutsche Bank Hold $17 → $35
Mar-04-14Reiterated Canaccord Genuity Hold $25 → $27
Jan-21-14Upgrade Needham Hold → Buy $36
Nov-26-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
Nov-13-13Downgrade Needham Buy → Hold
Nov-13-13Downgrade Deutsche Bank Buy → Hold $71 → $17
Nov-12-13Reiterated FBR Capital Mkt Perform $48 → $20
Oct-30-13Initiated FBR Capital Mkt Perform $48
Sep-06-13Initiated Stifel Buy $51
Apr-22-13Initiated Needham Buy $57
Apr-04-13Initiated Robert W. Baird Outperform $63
Apr-03-13Initiated Robert W. Baird Outperform $63
Mar-08-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
Nov-26-12Initiated Burrill Institutional Research Mkt Outperform $54
Sep-12-12Downgrade WBB Securities Hold → Sell $8 → $9
Dec-16-14 05:46PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT Marketwired
Dec-09-14 05:35PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Against Sarepta Therapeutics, Inc. to Recover Investor Losses -- SRPT GlobeNewswire +6.46%
03:32PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire
Dec-08-14 06:45PM  INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
Dec-05-14 06:00AM  Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta at TheStreet
Dec-02-14 11:00AM  Sarepta DMD Community Update Call scheduled for 11:00 am ET today CCBN
Nov-26-14 09:25AM  Sarepta Therapeutics upgraded by WBB Securities Briefing.com
Nov-24-14 05:24PM  It was another slow, low volume, lackluster trading session Yahoo Finance Blogs +5.59%
04:30PM  Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 Business Wire
12:26PM  Midday movers: 3D Systems, Kate Spade, Nike & more at CNBC
12:20PM  BioMarin's Prosensa Buy: A 'Courageous' Acquisition? at Barrons.com
10:22AM  BioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily
09:19AM  Stock Futures Trending Higher; Kate Spade Bags An Upgrade at Investor's Business Daily
07:00AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Nov-18-14 03:24PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Shareholders PR Newswire
09:15AM  Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy Business Wire
Nov-14-14 06:16PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Sarepta Therapeutics, Inc. (SRPT) To Contact The Firm PR Newswire
01:04PM  SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials
Nov-13-14 04:40PM  Sarepta Initiates Dosing for Study Evaluating Eteplirsen Zacks
10:21AM  A Day Of Reckoning Approaches For Merck And Its Critics at Forbes
Nov-12-14 05:15PM  Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy Business Wire
Nov-11-14 10:32AM  INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
Nov-10-14 04:14PM  SHAREHOLDER ALERT: Investigation on Behalf of Sarepta Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire
11:40AM  Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus Zacks
Nov-09-14 07:09PM  10-Q for Sarepta Therapeutics, Inc. Company Spotlight
Nov-06-14 08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN +7.19%
07:51AM  Sarepta Therapeutics tops 3Q profit forecasts AP
07:09AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
07:07AM  Q3 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments Business Wire
06:31AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
05:57AM  Investors eye earnings from film giants, biotech firms CNBC
Nov-05-14 05:56AM  Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) Zacks -7.39%
Nov-04-14 07:00AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
04:30AM  Tekmira Shares Surge Amid Promise of Ebola Treatment at Bloomberg
Oct-31-14 04:24PM  The rally that keeps on giving! Yahoo Finance Blogs
03:30PM  Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014 Business Wire
01:59PM  A 'Strange Back and Forth' Between Sarepta and the FDA at The Wall Street Journal
06:40AM  Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx at TheStreet
Oct-30-14 08:58PM  [$$] FDA Comments on Sarepta Drug Talks at The Wall Street Journal
Oct-28-14 04:42PM  Twitter and Amgen are big market movers AP
02:10PM  Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed Zacks
10:07AM  Story Stocks from Briefing.com Briefing.com
06:46AM  Sarepta Slumps: SRPT Plunges 32.5% in Session Zacks
12:56AM  [$$] Sareptas Muscular Dystrophy Drug Suffers Setback at The Wall Street Journal
Oct-27-14 06:06PM  Nasdaq stocks posting largest percentage decreases AP -32.47%
05:46PM  Prosensa pops on Sarepta FDA delay CNBC
04:34PM  S&P 500 trades in a narrow range, up against key technical levels Yahoo Finance Blogs
04:26PM  Merck good medicine? Talking Numbers
03:15PM  Market losers: Sarepta & Tesla CNBC
02:51PM  Sarepta Gets Delayed And The Stock Gets Drilled Benzinga
01:20PM  [$$] Muscular Dystrophy Drug Suffers Setback at The Wall Street Journal
01:15PM  Petrobras Plunges In The Wake Of Brazilian Election Results at TheStreet
12:29PM  3 Stocks, 3 trades: MRK, GRMN & SRPT CNBC
12:27PM  Sarepta Needs FDA Expertise, Stat at Forbes
11:41AM  Sarepta price target slashed by Piper Jaffray at MarketWatch
11:29AM  Sarepta Therapeutics: Don't Catch This Falling Knife at Barrons.com
11:10AM  Sarepta Faces Major Hurdle, and Not From Ebola at 24/7 Wall St.
11:02AM  Sarepta Shares Falls on Duchenne Drug Approval Filing Delay at TheStreet
10:54AM  Sarepta tumbles on new delay for key drug AP
09:47AM  Stocks to Watch: Chiquita, Allergan, Merck at The Wall Street Journal
09:02AM  Valeant may up bid for Allergan...again; Merck mixed results; Apple Pay mobile payment battle Hot Stock Minute
08:32AM  Biotech Stock Crashes After FDA Requires Additional Data For New Drug Application Business Insider
08:00AM  Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Call scheduled for 8:00 am ET today CCBN
07:36AM  Sarepta timeline delayed on muscular dystrophy drug at CNBC
07:20AM  Wall Street struggles to keep up momentum; Merck's profit tops estimates; Apple Pay gets a setback Hot Stock Minute
07:04AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Business Wire
Oct-24-14 02:58PM  Ebola stocks mostly higher after virus confirmed in New York at MarketWatch
10:53AM  Ebola's in New York; is the economy at risk? Yahoo Finance
Oct-21-14 06:45PM  Ebola vaccine could be ready in 3 months: CEO at CNBC
Oct-20-14 10:44AM  Ebola outbreak: Cashing in on a cure Yahoo Finance
06:10AM  A Promising Experimental Ebola Drug Goes Overlooked at BusinessWeek
Oct-17-14 12:00PM  10 biggest financial-market events this week at MarketWatch
10:58AM  Sarepta Therapeutics Shares Up On Ebola Drug Safety Study Benzinga
09:11AM  Carnival slides on Ebola fears; Urban Outfitters tumbles on sales warning; Morgan Stanley blows past estimates Hot Stock Minute
07:39AM  Ahead of the Bell: Sarepta Therapeutics climbs AP
07:27AM  Sarepta Is Surging After Good News For Its Ebola Treatment Business Insider
07:11AM  Stocks soar after volatile week; Housing starts rebounds; Starbucks offering free coffee and more Hot Stock Minute
Oct-16-14 07:38PM  [$$] Sarepta's Ebola Drug Showed No Ill Effects in Study at The Wall Street Journal +6.65%
05:27PM  Sarepta says its Ebola drug has no ill effects at MarketWatch
05:00PM  After-hours buzz: Google, SanDisk, Xilinx & more at CNBC
04:33PM  Sarepta says it sees no side effects from Ebola drug at MarketWatch
04:10PM  Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy Business Wire
02:05PM  Ebola Stocks on the Move at 24/7 Wall St.
Oct-15-14 04:30PM  Volatility at its finest Yahoo Finance Blogs +10.58%
Oct-13-14 04:30PM  Prosensa Starts Rolling NDA Submission for Drisapersen Zacks
01:06PM  [video] Funding pandemic preparedness at CNBC
01:00PM  [video] CDC: Won't block West African flights at CNBC
12:29PM  Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study at TheStreet
10:43AM  Questioning Ebola protocols CNBC
10:43AM  [video] Questioning Ebola protocols at CNBC
10:05AM  US nurses properly trained for Ebola? CNBC
10:05AM  [video] US nurses properly trained for Ebola? at CNBC
10:00AM  Ebola Fears Driving Ebola Stock Winners at 24/7 Wall St.
09:08AM  [video] Ebola: 1st US transmission at CNBC
08:24AM  [video] US hospital preparation in question at CNBC
07:06AM  [video] Ebola care learning curve at CNBC
07:01AM  [video] Health care worker diagnosed with Ebola at CNBC
06:01AM  [video] First US Ebola transmission at CNBC
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.